Structure-based design of 7-azaindole-pyrrolidine amides as inhibitors of 11 beta-hydroxysteroid dehydrogenase type I.
Valeur, E., Christmann-Franck, S., Lepifre, F., Carniato, D., Cravo, D., Charon, C., Bozec, S., Musil, D., Hillertz, P., Doare, L., Schmidlin, F., Lecomte, M., Schultz, M., Roche, D.(2012) Bioorg Med Chem Lett 22: 5909-5914
- PubMed: 22901389 
- DOI: https://doi.org/10.1016/j.bmcl.2012.07.070
- Primary Citation of Related Structures:  
3GMD - PubMed Abstract: 
Indole-pyrrolidines were identified as inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) by high-throughput screening. Optimisation of the initial hit through structure-based design led to 7-azaindole-derivatives, with the best analogues displaying single digit nanomolar IC(50) potency. The modeling hypotheses were confirmed by solving the X-ray co-crystal structure of one of the lead compounds. These compounds were selective against 11β-hydroxysteroid dehydrogenase type 2 (selectivity ratio >200) and exhibited good inhibition of 11β-HSD1 (IC(50)<1μM) in a cellular model (3T3L1 adipocytes).
Organizational Affiliation: 
Merck-Serono S.A., 9, Chemin des Mines, 1202 Geneva, Switzerland.